Personalised therapeutic cancer vaccine shows benefit in Phase III lymphoma trial
This article was originally published in Scrip
Biovest International's (Accentia Biopharmaceuticals) therapeutic cancer vaccine BiovaxID looks to have become the first to improve disease-free survival (DFS) in follicular lymphoma (FL) in the pivotal Phase III BV-301 study that was highlighted at a plenary session at the ASCO meeting in Orlando.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.